We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Malignant melanoma with in-transit metastases refractory to programmed cell death-1 inhibitor successfully treated with local interferon-β injections: A case report.
- Authors
Takahara, Yui; Kan, Takanobu; Teshima, Yoshie; Matsubara, Daiki; Takahagi, Shunsuke; Tanaka, Akio; Hide, Michihiro
- Abstract
In-transit metastases (ITMs) in patients with malignant melanoma (MM) are associated with poor prognosis and a worse disease burden compared with MM without ITMs. A substantial population of patients with ITMs show no or only poor responses to newly developed therapies, such as immune checkpoint inhibitors or molecular-targeted agents. It is difficult to control the exudate and bleeding from ITMs when these medications are ineffective. In Japan, local injection of interferon-β (IFN-β) has been licensed for years as adjuvant therapy for MM. However, the evidence for IFN-β effectiveness for ITMs remains low. The present report describes a case of MM with multiple ITMs that did not respond to a programmed cell death-1 inhibitor and local injections of IFN-β at 3 million IU/day for 5 days/4 weeks but remitted upon increasing the amount of IFN-β injections to 10 consecutive days/4 weeks. Local IFN-β therapy could be an option for improving the quality of life of patients.
- Subjects
JAPAN; TREATMENT effectiveness; MELANOMA; INJECTIONS; IMMUNE checkpoint inhibitors; PROGNOSIS; QUALITY of life
- Publication
Molecular & Clinical Oncology, 2021, Vol 15, Issue 4, pN.PAG
- ISSN
2049-9450
- Publication type
Article
- DOI
10.3892/mco.2021.2374